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Abstract
Background: Highly pathogenic avian H5N1 influenza virus is a major public health concern.
Given the lack of effective vaccine and recent evidence of antiviral drug resistance in some isolates,
alternative strategies for containment of a possible future pandemic are needed. Humanized
monoclonal antibodies (mAbs) that neutralize H5N1 virus could be used as prophylaxis and
treatment to aid in the containment of such a pandemic.
Methods: Neutralizing mAbs against H5 hemagglutinin were humanized and introduced into
C57BL/6 mice (1, 5, or 10 mg/kg bodyweight) one day prior to-, one day post- and three days post-
lethal challenge with H5N1 A/Vietnam/1203/04 virus. Efficacy was determined by observation of
weight loss as well as survival.
Results: Two mAbs neutralizing for antigenically variant H5N1 viruses, A/Vietnam/1203/04 and A/
Hong Kong/213/03 were identified and humanized without loss of specificity. Both antibodies
exhibited prophylactic efficacy in mice, however, VN04-2-huG1 performed better requiring only 1
mg/kg bodyweight for complete protection. When used to treat infection VN04-2-huG1 was also
completely protective, even when introduced three days post infection, although higher dose of
antibody was required.
Conclusion: Prophylaxis and treatment using neutralizing humanized mAbs is efficacious against
lethal challenge with A/Vietnam/1203/04, providing proof of principle for the use of passive
antibody therapy as a containment option in the event of pandemic influenza.
Background
With the initial outbreak of pneumonia caused by highly
pathogenic H5N1 influenza A virus in Hong Kong in
1997 resulting in the death of 6 of the 18 infected individ-
uals [1,2], the potential for emergence of a pandemic
influenza was recognized [3]. Mass slaughtering of poul-
try appeared to halt the outbreak. However, H5N1 viruses
of various genotypes have spread across Southeast Asia
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and have continued to cause disease outbreaks in poultry
and aquatic birds. Toward the end of 2003, a single geno-
type (the "Z-genotype") became dominant and was
responsible for outbreaks in Indonesia, Thailand and Viet-
nam throughout 2004 [4], causing death in ~50% of the
confirmed cases.
Since this time, the H5N1 influenza epidemic of the Asian
bird population has continued. In addition, infection of
migratory birds has resulted in increased global spread of
the virus with reports of H5N1 influenza causing mortal-
ity in poultry and aquatic birds throughout Asia, Europe
and Africa. From the beginning, the ability of H5N1
viruses to cross the species barrier was evident not only
from the cases of human infection, but also from infec-
tion and mortality in domestic cats, captive tigers and
leopards [5,6]. Taken together, the increased incidence of
human infection, coupled with evidence of expanding
host range and widespread distribution of H5N1 viruses
has heightened concern that acquisition of the properties
necessary, through mutation or genetic reassortment, for
human-to-human transmission is only a matter of time.
Should this occur, humans would have virtually no
immunity to such novel viruses which may result in a
human influenza pandemic of potentially catastrophic
proportions [7].
Currently, control of influenza relies on two options, vac-
cination or antiviral drug treatment with vaccination
being the preferred option. However, the high virulence of
H5N1 influenza has inhibited the development of vac-
cines using traditional approaches [8]. Other approaches
for vaccine production, such as reverse genetics, DNA vac-
cination and the use of recombinant hemagglutinin [8-
10], have been met with varying degrees of success but a
human vaccine ready for commercial production is still
not available. Therefore, should a pandemic arise due to
H5N1, the lack of an effective vaccine means containment
would rely solely on the effectiveness of antiviral drugs
and physical measures to inhibit viral spread such as
social distancing.
For treatment of influenza two classes of antiviral drugs
are presently licensed: M2 ion channel inhibitors (aman-
tadine and rimantadine) and neuraminidase inhibitors
(NAIs; oseltamivir and zanamivir). The presence of H5N1
viruses resistant to the M2 inhibitors [4,11], means their
use cannot be relied upon. The neuraminidase inhibitors
are currently viewed as the best choice for prophylaxis
against- and clinical management of- disease due to
H5N1 virus. Its efficacy in both uses is still unclear due to
a lack of human data. Recent studies in mice have high-
lighted prophylactic efficacy against infection by H5N1
virus isolated from Vietnam [12]. However, reports have
also appeared detailing the development of oseltamivir
resistance during treatment of H5N1 infected patients and
isolation of drug resistant H5N1 virus in the same region
[13,14]. While the current data does not deter stockpiling
of oseltamivir for pandemic response [15], it does suggest
that alternative strategies for prophylaxis or treatment are
warranted.
Passive immunization may provide an alternative strategy
for both prophylaxis and treatment against pandemic
influenza. For a number of viral diseases, such as rabies,
hepatitis and respiratory syncytial virus (RSV), adminis-
tration of antibodies derived from hyper-immune sera of
human or animal origin have been used effectively as
either prophylaxis or treatment in high risk individuals
where vaccination was not possible [16]. Indeed previous
studies have shown the effectiveness of neutralizing anti-
bodies specific for hemagglutinin as both a treatment for
established influenza A infection and prophylaxis against
influenza virus challenge in a mouse model [17-19].
Recently, equine hyperimmune globulin F(ab')2 has been
shown to effectively treat influenza A H5N1 virus infec-
tion in a mouse model [20], however use of animal
derived antibodies can result in severe anaphylactoid side
effects [21] and the induction of human anti-species spe-
cific antibody responses which limits the efficacy of the
antibodies with repeated use. We report here, the protec-
tive efficacy of neutralizing humanized monoclonal anti-
bodies specific for the hemagglutinin of a Z-genotype
influenza A H5N1 virus in mice when used as prophylaxis
before-, and treatment following-lethal challenge with
fully pathogenic H5N1 virus.
Methods
MAbs to Hemagglutinin of A/Vietnam/1203/04 (H5N1)
MAbs to the HA of A/Vietnam/1203/04 and A/Hong
Kong/213/03 were prepared in mice immunized with
attenuated versions of the respective H5N1 virus generate
by reverse genetics using a modification of the method
described by Kohler and Milstein [22,23].
Construction of human IgG1 constant region expression 
vector
Design of the expression vector for human IgG1 was based
on that described by Jostock et al, 2004 [24]. Briefly, a syn-
thetic construct containing the recognition sites for ApaL1,
Pst1, Asc1, Nco1, Mfe1, Xho1 and Xba1 with a synthetic
secretion leader sequence between Nco1 and Mfe1  was
used to replace the multiple cloning site, myc-tag and ER
retention signal of pCMV/myc/ER (Invitrogen). The inter-
nal ribosome entry site (IRES) of encephalomyocarditis
virus was inserted between Asc1  and  Nco1  following
amplification from pIRES (Clontech) to introduce the rel-
evant sites. For insertion of the human antibody constant
regions, cDNA clones (I.M.A.G.E. Consortium cDNA
clones [25]) encoding the Kappa light chain (Clone IDRespiratory Research 2006, 7:126 http://respiratory-research.com/content/7/1/126
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6279986) and the IgG1 heavy chain (Clone ID 6281248)
were amplified to allow insertion of the constant regions
between Pst1 and Asc1; and Xho1 and Xba1, respectively.
Recognition sites within the antibody constant regions
affecting cloning were removed by site-directed mutagen-
esis.
Cloning of chimeric IgG1 expression vectors
To isolate the cDNA encoding the variable regions of the
monoclonal antibodies, mRNA was prepared from hybri-
doma cells and used in first strand cDNA synthesis with
random hexa-nucleotides. The total cDNA was then used
as template in reactions to amplify both the variable
heavy and light chain using the primers and protocols of
the mouse scFv recombinant antibody phage system
(Amersham Biosciences) with the resulting products
cloned into pCR-Script (Stratagene) for sequencing. Vari-
able region specific primers were used to amplify both the
heavy and light chain variable regions with addition of
recognition sites to allow cloning between the Mfe1 and
Xho1; and ApaL1 and Pst1 sites of the human IgG1 con-
stant region expression vector, respectively. Cloning
according to this protocol produces constructs from
which expression gives rise to chimeric antibodies con-
taining the mouse variable and human constant regions.
Transient expression of chimeric antibodies and 
purification
Chimeric antibodies were expressed using the FreeStyle™
293 expression system (Invitrogen) to obtain antibodies
produced in a defined, serum-free medium. Constructs
encoding chimeric IgG1 were transfected into 293-F cells
by use of 293 fectin (Invitrogen). Supernatants were col-
lected 120 h after transfection and proteins purified using
protein A sepharose beads (Amersham). Purity of IgG was
confirmed using SDS-PAGE analyses. ELISA using HRP
labeled anti-mouse IgG (Sigma) and anti-human IgG
(Accurate Chemical & Scientific Corporation) was used to
highlight the introduction of human IgG constant regions
Virus neutralization and HI tests
Virus neutralization tests were performed in Madin Darby
canine kidney (MDCK) cells and hemagglutinin inhibi-
tion (HI) assays were performed with 0.5% chicken red
blood cells as previously described [22]. In each HI assay
four hemagglutinin units (HAUs) of virus were used and
100 50% tissue culture infective doses (TCID50) were used
in each of the virus neutralization tests.
Epitope mapping
Mapping of the epitope recognized by VN04-2 and VN04-
3 was performed using HI assay data as an indication of
antibody recognition, where high titer indicated strong
binding and low titers indicates negligible or non existent
binding. HI assay data from a recent paper that examined
the antigenic properties of multiple H5N1 sublineages,
using a number of mAbs against various H5N1 isolates
including VN04-2 (referred to as 15A3 in reference [26]),
was also included. Alignment of the H5 amino acid
sequences was and scattered mutations in positions not
common to all of the HI assay negative isolates were not
included in the examination.
Protection of mice with chimeric mAbs
All mouse studies were conducted under applicable laws
and guidelines of and after approval from the St. Jude
Children's Research Hospital Animal Care and Use Com-
mittee. Female 6–8 weeks old C57BL/6 mice (Jackson
Laboratories) were housed 5 per cage in ABSL3+ contain-
ment. Food and water were provided ad libitum. Mice (5
per group) received the indicated amount of antibody eg
1, 5 and 10 mg/kg of bodyweight in approximately 300 µL
of sterile phosphate-buffered saline (PBS) by intraperito-
neal (IP) injection. The control group received 300 µL of
PBS by IP. For lethal virus challenge, mice were inoculated
intranasally with 10 MLD50 (50% mouse lethal dose) in
30 µL of PBS of a fully virulent genetic clone of A/Viet-
nam/1203/04 virus derived by reverse genetics. This virus
is highly pathogenic in mice without prior adaptation and
symptoms preceding death are weight loss >30%, general
inactivity and the development of hind leg paralysis. For
the prophylaxis study, mice received the antibodies at the
indicated doses 24 hours prior to lethal virus challenge.
To determine therapeutic potential, mice were given a
lethal virus dose, followed by the indicated amounts of
antibody either one or three days post challenge. Morbid-
ity and mortality were monitored for 21 days and the mice
were weighed on days 4, 7, 10, 13 and 15 following virus
challenge.
Results
Characterization of H5 neutralizing mAbs
Monoclonal antibodies against H5N1 viruses of the Z
genotype which had shown high titers in HI tests against
their respective immunogens were tested for their virus
neutralizing capabilities. H5N1 viruses isolated from
human cases throughout late 2003 and 2004 were known
to differ in the antigenic loop located above the receptor
binding site, with a potential glycosylation site in the lat-
ter [22]. Antibodies binding to this antigenic loop are neu-
tralizing due to steric hindrance of the interaction
between the receptor binding site of HA and its receptor
located on the cell surface [27], glycosylation of this loop
may inhibit binding of the antibody destroying it virus
neutralizing properties. Therefore virus neutralization was
performed with A/Hong Kong/213/03 in addition to A/
Vietnam/1203/04 to allow identification of neutralizing
mAbs that were not dependant on this region for activity.
As highlighted in table 1 both VN04-2 and VN04-3 exhib-
ited similar virus neutralization titers with both of theRespiratory Research 2006, 7:126 http://respiratory-research.com/content/7/1/126
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H5N1 isolates, while VN04-6 and HK03-3 did not. There-
fore VN04-2 and VN04-3 were selected for humanization
and efficacy studies in a mouse model.
Humanization of H5N1 neutralizing mAbs
To humanize the mAbs, we constructed chimeric antibod-
ies where the coding regions of the mouse antibody vari-
able domains were fused to the coding region of the
constant domains of the human kappa light chain and
IgG1 heavy chain using the construct described in figure
1A. Both chimeric antibodies (VN04-2-huG1 and VN04-
3-huG1) were purified and their purity was confirmed by
SDS-PAGE analysis, where resolution characteristics of the
antibodies were observed and the preparation determined
to be essentially free of contaminants (data not shown).
Positive ELISA only in the presence of antibodies specific
for human IgG confirmed the humanization of the mouse
mAbs (figure 1B).
In order to ensure that humanization of the mAbs did not
destroy specificity; we examined the performance of the
humanized version of the antibodies in HI assays (table
2). For both VN04-2-huG1 and VN04-3-huG1, the titers
for the assays against A/Vietnam/1203/04 and A/Hong
Kong/213/03 indicated that the specificity was retained.
Prophylactic efficacy of VN04-2- and VN04-3 huG1 against 
A/Vietnam/1203/04 virus in vivo
To evaluate prophylactic efficacy of the chimeric antibod-
ies, VN04-2-huG1 and VN04-3-huG1 were introduced
into mice at the indicated doses twenty four hours prior to
lethal virus challenge. Mice receiving low doses of VN04-
2-huG1 antibody (1 mg/kg bodyweight) demonstrated
few clinical disease signs including weight loss and death
after virus challenge. Only one mouse lost more then 10%
of its original bodyweight with full recovery by day 15
(figure 2A). Increased amounts of this antibody (5 or 10
mg/kg bodyweight) completely protected mice from dis-
ease upon challenge (figure 2A and 2C). Prophylactic effi-
cacy was also observed for VN04-3-huG1, although not at
the extent of VN04-2-huG1, as three mice receiving 1 mg/
kg bodyweight showed significant weight loss of more
then 10% (figure 2B), two of which were found dead by
day 10 after virus challenge (figure 2C). Treatment with 5
mg/kg bodyweight of VN04-3-huG1 exhibited similar
efficacy as with 1 mg/kg bodyweight of VN04-2-huG1.
Finally, 10 mg/kg bodyweight of antibody VN04-3-huG1
completely protected mice from any clinical signs includ-
ing death after challenge with H5N1 virus.
Therapeutic efficacy of VN04-2-huG1 against A/Vietnam/
1203/04 virus in vivo
Since VN04-2-huG1 showed greater prophylactic efficacy
than VN04-3-huG1, therapeutic efficacy was determined
for this antibody alone. The indicated dosages of antibody
were introduced one and three days post lethal virus infec-
tion (figure 3). When the antibodies were given one day
after infection (figure 3A and 3B), 1 mg/kg bodyweight of
VN04-2-huG1 showed 80% protection, the remaining
mice did show significant signs of disease but recovered
by day 15. The higher doses of antibody (5 or 10 mg/kg
bodyweight) completely protected the mice and showed
little sign of disease. When antibodies were introduced
three days after infection (figure 3C and 3D), 10 mg/kg
bodyweight of VN04-2-huG1 was required to confer com-
plete protection, with lower doses (1 and 5 mg/kg body-
weight) showing 80% protection. The lower dosages of
antibody also showed increased signs of disease; however
Table 1: Virus-neutralization titers of mAbs against HA of H5N1
mAb to H5N1 HA
Virus VN04-2 VN04-3 VN04-6 HK03-3
A/Vietnam/1203/04 512 >512 >512 256
A/HK/213/03 512 >512 12 >512
Virus neutralization assays were performed in MDCK cells. Titers are the reciprocal lowest dilutions of mAbs that completely inhibited 100 TCID50 
of virus.
Table 2: HI assay testing of humanized mAbs against HA of H5N1
mAb to A/Vietnam/1203/04 HA
Virus VN04-2 VN04-2-huG1 VN04-3 VN04-3-huG1
A/Vietnam/1203/04 6400 400 3200 800
A/HK/213/03 6400 3200 6400 3200
HI assays were performed in microtiter plates with 0.5% chicken RBC. Titers are the reciprocal lowest dilutions of antibodies that inhibited 
hemagglutination caused by 4 HAU of virusRespiratory Research 2006, 7:126 http://respiratory-research.com/content/7/1/126
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all of the mice that did not succumb to infection recovered
the initial weight loss by day 15.
Epitope mapping
To determine the epitope on the H5 hemagglutinin pro-
tein recognized by VN04-2 and VN04-3, we examined the
amino acid differences between HAs of H5N1 viruses,
using HI assay results as a measure of antibody binding
(table 3). The majority of mutations occurred within the
140s and 150s antigenic loops identified from studies of
H3N2 which are positioned direct below and directly
above the receptor binding site, respectively [27]. Two
positions were identified which differed in all of the HI
assay negative isolates, amino acid 94 and amino acid 140
within the 140s loop. However the amino acid at position
94 faces the inside of the HA trimer and is unlikely to
affect antibody binding. Therefore the epitope recognized
by VN04-2 is most likely within or in close proximity to
140s antigenic loop, with residue 140 showing significant
contribution to the specificity as even viruses with muta-
tion only in this residue of the 140 loop were not inhib-
ited by the antibody in HI assays. Other residues of the
140 loop may also be important for antibody binding as
mutation at residues 138 and 141, as observed in A/Mdk/
Humanization of mouse mAbs VN04-2 and VN04-3 Figure 1
Humanization of mouse mAbs VN04-2 and VN04-3. A, Diagrammatic representation of the expression vector used to 
create chimeric antibodies; CL and CH refer to the constant regions of the human Kappa light and human IgG1, respectively; L 
refers to the leader sequence. B, ELISA to show presence of human constant regions, antibodies bound to immunosorbent 
plates were detected using secondary antibodies specific for human IgG and mouse IgG. Following addition of TMB substrate 
absorbance was measured at 450 nm.
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Prophylactic efficacy of VN04-2- and VN04-3-huG1 in mice Figure 2
Prophylactic efficacy of VN04-2- and VN04-3-huG1 in mice. Mice were challenged with a lethal dose (10 MLD50) of 
fully virulent A/Vietnam/1203/04 24 h after the introduction of 1, 5, or 10 mg/kg bodyweight of antibody. The percentage of ini-
tial body weight after challenge is indicated for VN04-2-huG1 (A) and VN04-3-huG1 (B) periodically over 15 days. Each data 
point represents the average of 5 mice. Survival of challenged mice was observed for 21 days after challenge and indicates the 
level of protection from mortality (C).
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Jiang Xi/1653/05, also lowered the inhibitory effect of
VN04-2 but not to the extent as did mutation of residue
140.
Discussion
In this study, we have reported the protective potential of
two mAb specific for hemagglutinin of a Z-genotype
H5N1 virus A/Vietnam/1203/04. Previous studies exam-
ining the antigenic sites of hemagglutinin of influenza A
H3N2 have identified two protruding loops, residues
140–146 (140s loop) and 155–164 (150s loop), located
near the receptor-binding site that are antibody-binding
sites for potent neutralizing antibodies against this virus
[28]. These loops are prone to antigenic drift and muta-
tion introducing a potential glycosylation into this region
inhibits antibody binding [28,29]. These antigenic loops
have also been identified in the hemagglutinin of H5N1
viruses by structural determination [30]. Comparison of
the amino acid sequences of numerous H5N1 hemagglu-
tinins shows genetic drift in these regions, and the intro-
Therapeutic efficacy of VN04-2-huG1 in mice Figure 3
Therapeutic efficacy of VN04-2-huG1 in mice. Mice were inoculated with a lethal dose (10 MLD50) of A/Vietnam/1203/
04 virus 24 h, followed by the introduction of 1, 5, or 10 mg/kg bodyweight of VN04-2-huG1 antibody one (A and B) and three 
(C and D) days post infection. The percentage of initial body weight was monitored periodically over 15 days (B and D) and each 
data point represents the average of 5 mice. Survival of mice was observed for 21 days following infection and indicates the 
level of protection from mortality (A and C).
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duction of a potential glycosylation site in the 150s loop
of virus isolated in Vietnam during 2004. Micro-neutrali-
zation assays using A/Vietnam/1203/04 and A/Hong
Kong/213/03, designed to select for antibodies not
dependant on the 150s loop for binding, identified two
mAb (VN04-2 and VN04-3) which showed similar levels
of neutralization against both H5N1 viruses.
Since the ultimate goal is to identify antibodies which can
be used as passive antibody prophylaxis against human
infection with H5N1 virus, we humanized the antibody
prior to efficacy studies by replacing the constant regions
of the mouse mAb with those of human IgG1 heavy chain
and kappa light chain. The chimeric antibodies retained
the specificity of the parent mouse mAbs. Humanization
is a complex issue (excellently reviewed [31]), designed to
overcome the problems associated with use of mouse
mAbs in humans, such as human anti-mouse-antibody
(HAMA) responses that limits their repeated use: the
extent of humanization versus the reduction of HAMA
response is still an open question. Some human anti-chi-
meric antibody responses have been observed, however
some human antibodies against more completely human-
ized mouse mAb have also been observed. Nevertheless,
antibodies humanized by both methods used therapeuti-
cally and repetitively in the same individual are evident
and the question of which is the best method still remains
open. Perhaps the ultimate test will be in phase 1 clinical
trials where the development of human antibodies
against the introduced humanized antibody can be exper-
imentally determined.
As a prelude to the possibility of testing the clinical appli-
cation of these antibodies in human trials, their efficacy in
an animal model needs to be determined. To this end,
protection against lethal virus infection in a C57BL/6
mouse model both in a prophylactic and therapeutic con-
text was performed. VN04-2-huG1 performed better in
vivo than VN04-3-huG1 as complete protection against
virus challenge with very little sign of disease with the
lowest tested antibody concentration of 1 mg/kg was
observed. This level of VN04-2-huG1 was not as effective
therapeutically when used one or three days after infec-
tion, as protection was reduced to 80% and significant
signs of disease were evident. However increasing the dos-
age of the antibody did restore complete protection and
limit illness. As expected, a correlation of antibody dosage
required for effective treatment versus the time of treat-
ment after infection was evident, as more antibody was
required to achieve similar therapeutic efficacy when the
antibodies were introduced three days after infection
compared to one day post infection. This result supports
the recent study showing therapeutic efficacy of equine
hyperimmune globulin F(ab')2 against H5N1 virus one
day post infection [20], and may allow for extension of
their therapeutic potential to three days post infection.
The efficacy of VN04-2-huG1 both as prophylaxis and
therapy suggests that this antibody should be considered
for further evaluation as a passive antibody prophylaxis
against H5N1 virus infection for use in humans.
A potential drawback to the use of passive antibodies is
the current high cost of large scale antibody production.
This raises the costs of treatments utilizing antibodies,
such as for RSV infection and autoimmune disease, to sev-
eral thousands of dollars per treatment. It is also worthy
of note that these antibodies are among the first commer-
cially available antibodies for clinical use, a factor which
contributes to the high cost and also that the amount of
antibody administered is very high. Should an influenza
pandemic arise, the increased burden on infrastructure as
well as the likely effect on tourism and international trade
would have a large impact on the economies of many
countries. Therefore, the widespread use of protective
antibodies to mitigate virus spread would become a gov-
ernmental decision, as faster economic recovery through
Table 3: Epitope mapping of VN04-2
Virus HI Titer Amino acid position in HA1
140s Loop 150s Loop
94 124 138 140 141 154 155 156
A/Vietnam/1203/04 +++ D S Q K SNST
A/Hong Kong/213/03 +++ . . . . .. N A
A/Dk/Hong Kong/2986.1/00* +++ . N . . ... A
A/Mdk/Jiang Xi/1653/05* ++ . N L . P..A
A/Mdk/Jiang Xi/2136/05* - N D . R .. N A
A/Dk/Vietnam/568/05* - N D . N .. D A
A/Qing Hai/05* - N D . R .. N A
Viruses where HI assay titer data was taken from Chen et al, 2006 [26] are highlighted by asterix. Residues matching that in A/Vietnam/1203/04 are 
represented by full stop. Residue numbering refers to the position in A/Vietnam/1203/04.Respiratory Research 2006, 7:126 http://respiratory-research.com/content/7/1/126
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decisive and rapid containment of a pandemic would
make the cost of the antibodies negligible when com-
pared to the cost of a prolonged pandemic. However, anti-
body dosage for every member of the population may not
be necessary. Recent studies examining containment strat-
egies for pandemic influenza using a combination of geo-
graphically targeted prophylaxis with antiviral drugs and
social distancing have suggested that a stockpile of 3 mil-
lion doses of antiviral may be sufficient to contain an
emerging pandemic at the source [32,33]. Given the effi-
cacy of VN04-2-huG1, it would not be unwarranted to
suggest that passive antibody therapy with these antibod-
ies could be used in a similar manner to antiviral drugs in
this model, drastically reducing the amount of antibody
needed for stockpiling to an achievable level.
While the antibodies described here are specific for the
hemagglutinin of H5N1 viruses of the Z-genotype circu-
lating in 2003/2004, the recent emergence of multiple
sublineages of H5N1 virus in Asia, some of which are anti-
genically distinct to those used here [26], raises the possi-
bility that a future pandemic influenza may escape the
protective effect of these antibodies. Indeed, determina-
tion of the epitope of VN04-2-huG1 using the HI data pre-
sented here and that detailed in the abovementioned
study identified the 140s antigenic loop as responsible for
antibody binding and suggests a requirement for lysine at
position 140. However it should be noted that all of the
HI assay negative strains contain a mutation at residue 94.
While this residue faces inside the hemagglutinin trimer
and would not be exposed for antibody binding, it may
still have an effect on the performance of the HI assays, as
was the case with mutation of a serine at position 223 to
asparagine [22], raising the possibility that the negative
result for the HI assays may be more a limitation of the
assay rather then the ability of the antibody to bind to the
virus. In either case, mutations within the antigenic loops
of hemagglutinin have been shown to effect antibody
binding and neutralization [34,35], and more recent iso-
lates of H5N1 virus have shown mutation from those cir-
culating in 2004 within these antigenic regions.
The effect of the mutations on the protective efficacy of
VN04-2-huG1 for influenza A H5N1 virus currently circu-
lating would have to be determined experimentally. If
indeed the 140s antigen loop is a major determinant of
the epitope for VN04-2-huG1, then a future pandemic
strain may escape the protection afforded by this anti-
body. To combat such an outcome, a panel of proven pro-
tective antibodies could be established against multiple
antigenic loop variants. Although, the question of muta-
tion within the antigenic regions of a future pandemic
strain allowing escape would still be an important issue.
Ideally, a neutralizing antibody whose epitope determi-
nants are not within the antigenic loops and less prone to
mutation may somewhat overcome this issue, but the
ability to identify such an antibody may not be possible.
Nevertheless, we have shown here the 'proof of principle'
that passive antibody therapy can be an effective tool for
both prophylaxis against- and treatment of- highly patho-
genic H5N1 influenza virus, providing the immediate
immunity needed which combined with social distancing
could limit the transmission of H5N1 virus to others and
contain a future influenza pandemic.
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